These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Caffeine and halothane contracture testing in swine using the recommendations of the North American Malignant Hyperthermia Group. Allen GC; Fletcher JE; Huggins FJ; Conti PA; Rosenberg H Anesthesiology; 1990 Jan; 72(1):71-6. PubMed ID: 2297135 [TBL] [Abstract][Full Text] [Related]
11. Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group. Larach MG Anesth Analg; 1989 Oct; 69(4):511-5. PubMed ID: 2675676 [No Abstract] [Full Text] [Related]
12. The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS. Allen GC; Larach MG; Kunselman AR Anesthesiology; 1998 Mar; 88(3):579-88. PubMed ID: 9523799 [TBL] [Abstract][Full Text] [Related]
13. Neuroleptic malignant syndrome and malignant hyperthermia. In vitro comparison with halothane and caffeine contracture tests. Krivosic-Horber R; Adnet P; Guevart E; Theunynck D; Lestavel P Br J Anaesth; 1987 Dec; 59(12):1554-6. PubMed ID: 3426910 [TBL] [Abstract][Full Text] [Related]
14. Malignant hyperthermia in humans--standardization of contracture testing protocol. Melton AT; Martucci RW; Kien ND; Gronert GA Anesth Analg; 1989 Oct; 69(4):437-43. PubMed ID: 2782643 [TBL] [Abstract][Full Text] [Related]
15. Between-center variability of results of the in vitro contracture test for malignant hyperthermia susceptibility. Ording H; Islander G; Bendixen D; Ranklev-Twetman E Anesth Analg; 2000 Aug; 91(2):452-7. PubMed ID: 10910867 [TBL] [Abstract][Full Text] [Related]
16. Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine- and the ryanodine-contracture-test results in MH susceptible, normal and control muscle. Hartung E; Koob M; Anetseder M; Schoemig P; Krauspe R; Hogrefe G; Engelhardt W Acta Anaesthesiol Scand; 1996 Apr; 40(4):437-44. PubMed ID: 8738688 [TBL] [Abstract][Full Text] [Related]
17. Does prior dantrolene affect the in vitro diagnosis of malignant hyperthermia susceptibility? Nelson TE; Flewellen EH Can Anaesth Soc J; 1979 Nov; 26(6):484-8. PubMed ID: 526874 [TBL] [Abstract][Full Text] [Related]
18. The in vitro determination of susceptibility to malignant hyperthermia. Iaizzo PA; Lehmann-Horn F Muscle Nerve; 1989 Mar; 12(3):184-90. PubMed ID: 2725548 [TBL] [Abstract][Full Text] [Related]
19. [Contracture test with ionophore A 23187 for the diagnosis of malignant hyperthermia]. Moeller R; Kozak-Reiss G; Gascard JP; Laxenaire MC Ann Fr Anesth Reanim; 1986; 5(2):177-81. PubMed ID: 3089080 [TBL] [Abstract][Full Text] [Related]
20. Contractile elements in muscular fascial tissue - implications for in-vitro contracture testing for malignant hyperthermia. Hoppe K; Schleip R; Lehmann-Horn F; Jäger H; Klingler W Anaesthesia; 2014 Sep; 69(9):1002-8. PubMed ID: 24909539 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]